# Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies (Companion Faculty Lecture)

An episode of [Research To Practice | Oncology Videos](https://invisiblenetwork.ai/podcast/699146770), 5 Oct 2026, 28 min.

Audio: https://traffic.libsyn.com/secure/researchtopractice/Budde_8-28-26_Presentation_V1FC_TW_480.mp4?dest-id=1103750

Featuring a slide presentation and related discussion from Dr L Elizabeth Budde, including the following topics: • Overview of approved and investigational CD20 x CD3 bispecific antibodies (BsAbs) in non-Hodgkin lymphoma; key findings from Phase II studies evaluating glofitamab and epcoritamab in relapsed/refractory (R/R) diffuse large B-cell lymphoma (0:00) • Bringing BsAbs into earlier-line settings; key findings from Phase III studies (7:49) • Key findings from the Phase III EPCORE DLBCL-1 and EPCORE DLBCL-4 studies and Phase II EPCORE NHL-1 study (14:12) • A Phase Ib/II study of glofitamab/polatuzumab in R/R large B-cell lymphoma; investigating the use of BsAbs as front-line therapy and as combination therapy (17:58) • Managing treatment-related adverse events; final takeaways (22:53) CME information and select publications

Shows are listed from Apple Podcasts' charts and directory, and Podcast Index where it is used. Every show and episode belongs to its publisher and plays from the publisher's own feed; this site hosts none of them.